SEC Form 4 · accession 0002013156-26-000007
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Philip L Johnson
Officer — EVP & Chief Financial Officer
Period of report
Jun 30, 2026
Accepted (ET)
Jul 2, 2026 · 6:04 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF2 | Jun 30, 2026 | F | 3,343 | $237.72 | D | 56,431 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
- F2The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026.